Company intelligence / Profile preview
Sharp Therapeutics
Pittsburgh, Pennsylvania, United Statessharptx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Company is developing small molecule drugs for genetic diseases, with plans to nominate their first clinical candidate in Q2 2025 and begin patient testing in 2026
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Sharp Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sharp Therapeutics.